The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a)
Abstract
Lipoprotein(a) [Lp(a)] has been measured in numerous clinical and epidemiological studies by a variety of immunochemical methods. However, little, if any, consideration has been given to the confounding effect of the size heterogeneity of apolipoprotein(a) [apo(a)] on the measurement of Lp(a). We developed three direct-binding enzyme-linked immunosorbent assays (ELISAs) with detecting antibodies of different specificities to evaluate the effect of apo(a) size on Lp(a) measurement. The three assays used the same monoclonal antibody to capture the apo(a)-containing particles and were calibrated (in nanomoles per liter) with a serum containing apo(a) with 21 kringle 4 domains. Using all three ELISAs, we measured Lp(a) in a group of 723 subjects selected to have a single apo(a) band, as determined by a high-resolution phenotyping system. Essentially identical results were obtained by the two methods that measured Lp(a) by use of either a polyclonal antibody against apo B or a monoclonal antibody against apo(a) that does not recognize the kringle 4 type 2 repeats. In contrast, the ELISA using a monoclonal antibody specific for apo(a) kringle 4 type 2 repeats overestimated Lp(a) concentration in samples containing apo(a) with more than 21 kringle 4 domains and underestimated Lp(a) samples containing apo(a) with fewer than 21 kringle 4 domains. Thus, these differences in Lp(a) values varied as a function of apo(a) size. We conclude that antibody specificity and apo(a) size heterogeneity can significantly affect Lp(a) measurements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Towbin, H., Staehelin, T., & Gordon, J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4350 · Cited by 53,385
THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS
Scatchard, G. (1949) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1949.tb27297.x · Cited by 19,778
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451
Characteristics of a human cell line transformed by DNA from human adenovirus type 5
Graham, F. L., Russell, W. C., Smiley, J., & Nairn, R. (1977) · Journal of General Virology · doi:10.1099/0022-1317-36-1-59 · Cited by 4,793
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
McLean, J. W., Tomlinson, J. E., Kuang, W.-J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., & Lawn, R. M. (1987) · Nature · doi:10.1038/330132a0 · Cited by 1,886 · cited 2×
“Calculation of the molar concentration of Lp(a) was based on the concentrations of alanine, aspartic acid, glutamic acid, leucine, lysine, and phenylalanine, and the combined amino acid composition of apo(a) and apo B-100 obtained from the published protein sequences for apo B-100 (21) and apo(a) (2).”
BackgroundMethodA Parathyroid Hormone-Related Protein Implicated in Malignant Hypercalcemia: Cloning and Expression
Suva, L. J., Winslow, G. A., Wettenhall, R. E. H., Hammonds, R. G., Moseley, J. M., Diefenbach-Jagger, H., Rodda, C. P., Kemp, B. E., Rodriguez, H., Chen, E. Y., et al. (1987) · Science · doi:10.1126/science.3616618 · Cited by 1,293
Chait, A., Brazg, R. L., Tribble, D. L., & Krauss, R. M. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90144-e · Cited by 554
Molecular definition of the extreme size polymorphism in apolipoprotein(a)
Lackner, C., Cohen, J. C., & Hobbs, H. H. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.933 · Cited by 319
Fless, G. M., ZumMallen, M. E., & Scanu, A. M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)84439-3 · Cited by 274
Marcovina, S. M., Zhang, Z. H., Gaur, V. P., & Albers, J. J. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1343 · Cited by 225
Self-citation
Cited by
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381
A Test in Context: Lipoprotein(a)
Tsimikas, S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.042 · Cited by 1,137
“Within populations, there is extensive apo(a) protein size heterogeneity, with >40 different isoforms, and thus, >40 different sizes of Lp(a) particles, which is a unique occurrence unlike other circulating proteins, which usually have 1 defined mass (5).”
BackgroundReyes-Soffer, G., Ginsberg, H. N., Berglund, L., Duell, P. B., Heffron, S. P., Kamstrup, P. R., Lloyd-Jones, D. M., Marcovina, S. M., Yeang, C., Koschinsky, M. L., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000147 · Cited by 836
Self-citationAtherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors
Périard, D., Telenti, A., Sudre, P., Cheseaux, J.-J., Halfon, P., Reymond, M. J., Marcovina, S. M., Glauser, M. P., Nicod, P., Darioli, R., et al. (1999) · Circulation · doi:10.1161/01.cir.100.7.700 · Cited by 605
Self-citationNordestgaard, B. G., & Langsted, A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r071233 · Cited by 575
O’Brien, K. D., Reichenbach, D. D., Marcovina, S. M., Kuusisto, J., Alpers, C. E., & Otto, C. M. (1996) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.16.4.523 · Cited by 560
Self-citationKamstrup, P. R., Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2008) · Circulation · doi:10.1161/circulationaha.107.715698 · Cited by 558
Lipoprotein(a): resurrected by genetics
Kronenberg, F., & Utermann, G. (2013) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02592.x · Cited by 521
Wilson, D. P., Jacobson, T. A., Jones, P. H., Koschinsky, M. L., McNeal, C. J., Nordestgaard, B. G., & Orringer, C. E. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.04.010 · Cited by 518
Self-citationTsimikas, S., Fazio, S., Ferdinand, K. C., Ginsberg, H. N., Koschinsky, M. L., Marcovina, S. M., Moriarty, P. M., Rader, D. J., Remaley, A. T., Reyes-Soffer, G., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.014 · Cited by 501
Self-citationPurnell, J. Q., Hokanson, J. E., Marcovina, S. M., Steffes, M. W., Cleary, P. A., & Brunzell, J. D. (1998) · JAMA · doi:10.1001/jama.280.2.140 · Cited by 469
Self-citationTsimikas, S., Viney, N. J., Hughes, S. G., Singleton, W., Graham, M. J., Baker, B. F., Burkey, J. L., Yang, Q., Marcovina, S. M., Geary, R. S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61252-1 · Cited by 460
Self-citationEffect of ritonavir on lipids and post-heparin lipase activities in normal subjects
Purnell, J. Q., Zambon, A., Knopp, R. H., Pizzuti, D. J., Achari, R., Leonard, J. M., Locke, C., & Brunzell, J. D. (2000) · AIDS · doi:10.1097/00002030-200001070-00006 · Cited by 387
Shlipak, M. G. (2000) · JAMA · doi:10.1001/jama.283.14.1845 · Cited by 371
Plenge, J. K., Hernandez, T. L., Weil, K. M., Poirier, P., Grunwald, G. K., Marcovina, S. M., & Eckel, R. H. (2002) · Circulation · doi:10.1161/01.cir.0000029743.68247.31 · Cited by 354
Self-citationLipoprotein (a) measurements for clinical application
Marcovina, S. M., & Albers, J. J. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r061648 · Cited by 338
Self-citationVirani, S. S., Brautbar, A., Davis, B. C., Nambi, V., Hoogeveen, R. C., Sharrett, A. R., Coresh, J., Mosley, T. H., Morrisett, J. D., Catellier, D. J., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.045120 · Cited by 324
Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes
Albers, J. J., Slee, A., O'Brien, K. D., Robinson, J. G., Kashyap, M. L., Kwiterovich, P. O., Xu, P., & Marcovina, S. M. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.06.051 · Cited by 318
Self-citationMarcovina, S. M., Albers, J. J., Scanu, A. M., Kennedy, H., Giaculli, F., Berg, K., Couderc, R., Dati, F., Rifai, N., Sakurabayashi, I., et al. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.12.1956 · Cited by 313
Self-citationEffects of Lowering Elevated LDL Cholesterol on the Cardiovascular Risk of Lipoprotein(a)
Maher, V. M. G. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530220037029 · Cited by 298
Kronenberg, F., Kronenberg, M. F., Kiechl, S., Trenkwalder, E., Santer, P., Oberhollenzer, F., Egger, G., Utermann, G., & Willeit, J. (1999) · Circulation · doi:10.1161/01.cir.100.11.1154 · Cited by 293
Marcovina, S. M., Koschinsky, M. L., Albers, J. J., & Skarlatos, S. (2003) · Clinical Chemistry · doi:10.1373/clinchem.2003.023689 · Cited by 288
Self-citationBennet, A. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.6.598 · Cited by 281
Zambon, A., Hokanson, J. E., Brown, B. G., & Brunzell, J. D. (1999) · Circulation · doi:10.1161/01.cir.99.15.1959 · Cited by 263
Lipoprotein (a): impact by ethnicity and environmental and medical conditions
Enkhmaa, B., Anuurad, E., & Berglund, L. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r051904 · Cited by 260
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)
Koren, M. J., Moriarty, P. M., Baum, S. J., Neutel, J., Hernandez-Illas, M., Weintraub, H. S., Florio, M., Kassahun, H., Melquist, S., Varrieur, T., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01634-w · Cited by 239
Romagnuolo, R., Scipione, C. A., Boffa, M. B., Marcovina, S. M., Seidah, N. G., & Koschinsky, M. L. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.611988 · Cited by 206
Self-citationArgraves, K. M., Kozarsky, K. F., Fallon, J. T., Harpel, P. C., & Strickland, D. K. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119753 · Cited by 146
Tsimikas, S., Fazio, S., Viney, N. J., Xia, S., Witztum, J. L., & Marcovina, S. M. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.07.003 · Cited by 109
Self-citationRecycling of Apolipoprotein(a) After PlgRKT-Mediated Endocytosis of Lipoprotein(a)
Sharma, M., Redpath, G. M., Williams, M. J. A., & McCormick, S. P. A. (2017) · Circulation Research · doi:10.1161/circresaha.116.310272 · Cited by 97
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study
Parish, S., Hopewell, J. C., Hill, M. R., Marcovina, S., Valdes-Marquez, E., Haynes, R., Offer, A., Pedersen, T. R., Baigent, C., Collins, R., et al. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.117.001696 · Cited by 93
Self-citationGalactose-specific asialoglycoprotein receptor is involved in lipoprotein (a) catabolism
HRZENJAK, A., FRANK, S., WO, X., ZHOU, Y., van BERKEL, T., & KOSTNER, G. M. (2003) · Biochemical Journal · doi:10.1042/bj20030932 · Cited by 51
Update on the laboratory investigation of dyslipidemias
Ramasamy, I. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.01.015 · Cited by 50
Sharma, M., Von Zychlinski-Kleffmann, A., Porteous, C. M., Jones, G. T., Williams, M. J. A., & McCormick, S. P. A. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m056150 · Cited by 32
Carr, M. C., Knopp, R. H., Brunzell, J. D., Wheeler, B. S., Zhu, X., Lakshmanan, M., Rosen, A. S., & Anderson, P. W. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1555 · Cited by 22
Metadata
- Authors
- Marcovina, S. M., Albers, J. J., Gabel, B., Koschinsky, M. L., & Gaur, V. P.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 1995-02-01
- Volume
- 41
- Issue
- 2
- Pages
- 246-255
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W1907534963
- Cited by
- 354
- References
- 19
- FWCI
- 23.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.